Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Smoothened is a master regulator of adult liver repair
Gregory A. Michelotti, … , Daniel Metzger, Anna Mae Diehl
Gregory A. Michelotti, … , Daniel Metzger, Anna Mae Diehl
Published April 8, 2013
Citation Information: J Clin Invest. 2013;123(6):2380-2394. https://doi.org/10.1172/JCI66904.
View: Text | PDF
Research Article Hepatology

Smoothened is a master regulator of adult liver repair

  • Text
  • PDF
Abstract

When regenerative processes cannot keep pace with cell death, functional epithelia are replaced by scar. Scarring is characterized by both excessive accumulation of fibrous matrix and persistent outgrowth of cell types that accumulate transiently during successful wound healing, including myofibroblasts (MFs) and progenitors. This suggests that signaling that normally directs these cells to repair injured epithelia is deregulated. To evaluate this possibility, we examined liver repair during different types of liver injury after Smoothened (SMO), an obligate intermediate in the Hedgehog (Hh) signaling pathway, was conditionally deleted in cells expressing the MF-associated gene, αSMA. Surprisingly, blocking canonical Hh signaling in MFs not only inhibited liver fibrosis but also prevented accumulation of liver progenitors. Hh-sensitive, hepatic stellate cells (HSCs) were identified as the source of both MFs and progenitors by lineage-tracing studies in 3 other strains of mice, coupled with analysis of highly pure HSC preparations using flow cytometry, immunofluorescence confocal microscopy, RT-PCR, and in situ hybridization. The results identify SMO as a master regulator of hepatic epithelial regeneration based on its ability to promote mesenchymal-to-epithelial transitions in a subpopulation of HSC-derived MFs with features of multipotent progenitors.

Authors

Gregory A. Michelotti, Guanhua Xie, Marzena Swiderska, Steve S. Choi, Gamze Karaca, Leandi Krüger, Richard Premont, Liu Yang, Wing-Kin Syn, Daniel Metzger, Anna Mae Diehl

×

Figure 2

Blocking Hh signaling inhibits portal tract expansion and fibrosis in injured livers.

Options: View larger image (or click on image) Download as PowerPoint
Blocking Hh signaling inhibits portal tract expansion and fibrosis in in...
(A) H&E staining of liver sections from representative vehicle- and TMX-treated DTG mice 14 days after sham surgery or BDL (original magnification, ×4). Portal tract size was evaluated by morphometric analysis of H&E-stained sections from all mice (n = 4 mice in sham vehicle; n = 4 mice in sham TMX; n = 11 mice in BDL vehicle; n = 11 mice BDL TMX), expressed as mean ± SEM of portal tract size, and graphed relative to vehicle-treated sham-operated mice. *P < 0.05 vs. vehicle-treated sham group. (B) Other sections were stained with Sirius red/fast green to demonstrate fibrosis (original magnification, ×4). Morphometric data are displayed as mean ± SEM. *P < 0.05 vs. vehicle-treated DTG mice after BDL. (C) Total liver RNA was isolated, and Col1a1 mRNA levels were analyzed by qRT-PCR. Results are expressed as fold over vehicle-treated sham-operated DTG group. *P < 0.05 vs. vehicle-treated BDL group. (D) Quantification of hepatic hydroxyproline in the respective groups. Results are expressed relative to vehicle-treated sham-operated DTG group. *P < 0.05 vs. vehicle-treated BDL group.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts